The Incidence and Survival of Rare Cancers of the Thyroid, Parathyroid, Adrenal, and Pancreas
- 388 Downloads
With the exception of papillary and follicular thyroid cancer, malignant cancers of the thyroid, parathyroid, adrenal, and endocrine pancreas are uncommon. These rare malignancies present a challenge to both the clinician and patient, because few data exist on their incidence or survival. We analyzed the incidence and survival of these rare endocrine cancers (RECs), as well as the trends in incidence over time.
We used the NCI’s SEER 18 database (2000–2012) to investigate incidence and survival of rare cancers of the thyroid, parathyroid, adrenal, and endocrine pancreas. Cancers were categorized using the WHO classification systems. We collected data on incidence, gender, stage, size, and survival. Time trends were evaluated from 2000–2002 to 2010–2012.
We identified 36 types of rare cancers in the endocrine organs captured in the SEER database. RECs of the thyroid had the highest combined incidence rate (IR 8.26), followed by pancreas (IR 3.24), adrenal (IR 2.71), and parathyroid (IR 0.41). The incidence rate for all rare endocrine organs combined increased 32.4 % during the study period. The majority of the increase was attributable to rare cancers of thyroid, which increased in not only microcarcinomas, but in all sizes. The mean 5-year survival for RECs is 59.56 % (range 2.49–100 %).
This study is a comprehensive analysis of the incidence and survival for rare malignant endocrine cancers. There has been an increase in incidence rate of almost all RECs and their survival is low. We hope that our data will serve as a source of information for clinicians as well as bring awareness regarding these uncommon cancers.
KeywordsIncidence Rate Adrenal Gland Parathyroid Gland Papillary Thyroid Cancer Parathyroid Carcinoma
This project was supported by the University of Chicago Bucksbaum Institute for Clinical Excellence. RHG was supported by Award Number K12CA139160 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or The National Institutes of Health.
Funding was provided by internal sources from the Department of Surgery at the University of Chicago.
There are no relevant conflicts of interests by any of the authors.
- 1.Very rare cancers—a problem neglected. Lancet Oncol. 2001;2(4):189.Google Scholar
- 4.Rare Diseases Act of 2002. Public law 170-280. http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=170_cong_public_laws&docid=f:publ280.107.
- 5.Orphan Drug Act. Washington, DC: US House of Representatives; (September 17), 1982. US House of Representatives report 97-840.Google Scholar
- 13.Surveillance, Epidemiology, and End Results (SEER) Program. Public-Use Database (1973–2009), National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2012, based on the November 2011 submission. http://seer.cancer.gov. Accessed Aug 2013.
- 14.Johnson CH, Adamo M, eds. SEER program coding and staging manual 2007 (NIH Publication number 07-5581). Bethesda: National Cancer Institute; 2007.Google Scholar
- 15.Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.Google Scholar
- 16.Surveillance Research Program, National Cancer Institute SEER*Stat software. Version 8.1.5. www.seer.cancer.gov/seerstat. Accessed Sept 2014.